Form 4: Hims & Hers Health Chief Legal Officer Sells Shares Under 10b5-1 Plan

Soleil Boughton, Chief Legal Officer of Hims & Hers Health, sold 2,338 shares of Class A Common Stock at $26.46 per share on November 12, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Soleil Boughton, the Chief Legal Officer of Hims & Hers Health, sold 2,338 shares of Class A Common Stock on November 12, 2024.
• The sale was executed at a price of $26.46 per share.
• This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 10, 2023.
• Following the transaction, Boughton directly owns 167,597 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to an executive's stock sale under a pre-arranged plan. It doesn't indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 plans to manage their stock sales and avoid accusations of trading on inside information.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a common practice among executives at publicly traded companies, including those in the healthcare and technology sectors, such as Teladoc Health and GoodRx.
• These plans allow insiders to sell shares at predetermined times and prices, mitigating the risk of insider trading allegations.
• The volume of shares sold by Soleil Boughton is relatively small compared to the total outstanding shares of Hims & Hers Health, and is not unusual for an executive's planned sales.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on shareholder sentiment, but is unlikely to significantly affect the stock price given the pre-planned nature of the transaction.

Key Dates

Keywords

Hims & Hers Health, insider trading, Rule 10b5-1, stock sale, equity securities, Chief Legal Officer, HIMS